A Propensity Score-Matched, Real-World Comparison of Ustekinumab Vs Vedolizumab As a Second-Line Treatment for Crohn's Disease. the Cross Pennine Study II
Alimentary Pharmacology & Therapeutics(2021)
关键词
Treatment
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要